Insights into the Evolution of Life Sciences and Investments

Elliot Turner, Managing Partner and CIO of RGIA Investment Advisors, returns to The Business Brew for a great conversation. To start, Bill and Elliot discuss what Elliot learned from the period of 2021 to now. They then discuss some specific stock ideas, thoughts on portfolio management, and much more. We hope you enjoy.

Note: This episode was recorded on April 3, 2024. Bill owns a small position in Fevertree (established after recording) and a basket of positions in some smaller life science companies.

Detailed Show Notes:

3:00 - Learnings

10:30 - Prioritizing health to lead to success

14:00 - Was it an everything bubble?

22:15 - Fevertree discussion

37:40 - Thoughts on position sizing

44:30 - Incentives in finance papers

49:00 - A great NVDA story

55:00 - Is life sciences similar to tech after 2000

58:50 - The 3 forces that make life sciences and biotech interesting for humanity

1:08:00 - Is The Street focused on the wrong things?

1:16:20 - Maravai

1:25:00 - Thinking about patent cliffs

1:29:00 - High costs of failure and why that may be a good opportunity for existing suppliers